On Friday, August 27, 2010, an official from the Drug Enforcement Administration (DEA) informed Michael Mithoefer, M.D. that it had approved his Schedule 1 license for MAPS’ MDMA/PTSD study in veterans with PTSD.
Obtaining the DEA’s approval was our final regulatory requirement. The DEA has now joined the FDA and our Independent Review Board (IRB) by determining it is in the public interest for MAPS’ study of MDMA-assisted psychotherapy in treating veterans of war to proceed.
